T. D. Cheng, S. M. Cramb, P. D. Baade, D. R. Youlden, C. Nwogu et al., The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics, Journal of Thoracic Oncology, vol.11, issue.10, 2016.
DOI : 10.1016/j.jtho.2016.05.021

M. Johnson and . Meyerson, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, vol.304, 2004.

L. Rusch, E. Fulton, D. Mardis, R. Kupfer, M. Wilson et al., EGF receptor gene mutations are common in lung cancers from " never smokers " and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc. Natl. Acad. Sci. U. S. A, vol.101, pp.13306-13311, 2004.

D. A. Settleman and . Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med, vol.350, pp.2129-2139, 2004.

S. Y. Luo and D. C. Lam, Oncogenic driver mutations in lung cancer, Translational Respiratory Medicine, vol.1, issue.1, pp.10-1186, 2013.
DOI : 10.1016/j.ccr.2006.04.022

D. J. Jenkins, J. Kwiatkowski, J. Saldivar, E. Squire, M. Thunnissen et al., null College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology, Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology, J. Mol. Diagn. JMD, vol.15, pp.415-453, 2013.

D. Mancini, E. Moro-sibilot, and S. Brambilla, Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: influence of ATS/ERS/IASLC guidelines, Lung Cancer Amst. Neth, pp.82-69, 2013.

S. Rizzo, F. Petrella, V. Buscarino, F. De-maria, S. Raimondi et al., CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer, European Radiology, vol.268, issue.1, pp.32-42, 2016.
DOI : 10.1007/s00330-015-3814-0

S. Yamamoto, R. L. Korn, R. Oklu, C. Migdal, M. B. Gotway et al., ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization, Radiology, pp.272-568, 2014.

B. Ganeshan and K. A. Miles, Quantifying tumour heterogeneity with CT, Cancer Imaging Off

F. Ng, R. Kozarski, B. Ganeshan, and V. Goh, Assessment of tumor heterogeneity by CT texture analysis: Can the largest cross-sectional area be used as an alternative to whole tumor analysis?, European Journal of Radiology, vol.82, issue.2, pp.342-348, 2013.
DOI : 10.1016/j.ejrad.2012.10.023

R. Meagher, S. A. Endozo, S. Taylor, P. J. Halligan, A. M. Ell et al., Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer, J. Nucl. Med. Off. Publ. Soc. Nucl. Med, vol.55, pp.386-391, 2014.

G. J. Weiss, B. Ganeshan, K. A. Miles, D. H. Campbell, P. Y. Cheung et al., Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic, PloS One, vol.9

A. M. Rutman and M. D. Kuo, Radiogenomics: Creating a link between molecular diagnostics and diagnostic imaging, European Journal of Radiology, vol.70, issue.2, pp.232-241, 2009.
DOI : 10.1016/j.ejrad.2009.01.050

J. Zugazagoitia, A. B. Enguita, J. A. Nuñez, L. Iglesias, and S. Ponce, The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects, J. Thorac. Dis, vol.6, pp.526-536, 2014.

A. Mcleer-florin, D. Moro-sibilot, A. Melis, D. Salameire, C. Lefebvre et al., Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study, Journal of Thoracic Oncology, vol.7, issue.2
DOI : 10.1097/JTO.0b013e3182381535

S. Dufort, M. Richard, S. Lantuejoul, and F. De-fraipont, Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC, Journal of Experimental & Clinical Cancer Research, vol.30, issue.1
DOI : 10.1158/1078-0432.CCR-05-2324

URL : https://hal.archives-ouvertes.fr/inserm-00602408

S. Dufort, M. Richard, and F. De-fraipont, Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues, Analytical Biochemistry, vol.391, issue.2, 2009.
DOI : 10.1016/j.ab.2009.05.027

K. A. Miles, B. Ganeshan, and M. P. Hayball, CT texture analysis using the filtration-histogram method: what do the measurements mean?, Cancer Imaging, vol.13, issue.3, pp.400-406, 2013.
DOI : 10.1102/1470-7330.2013.9045

B. Ganeshan, K. Skogen, I. Pressney, D. Coutroubis, and K. Miles, Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: Preliminary evidence of an association with tumour metabolism, stage, and survival, Clinical Radiology, vol.67, issue.2, pp.157-164, 2012.
DOI : 10.1016/j.crad.2011.08.012

B. Ganeshan, E. Panayiotou, K. Burnand, S. Dizdarevic, and K. Miles, Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival, European Radiology, vol.36, issue.4 Suppl, pp.796-802, 2012.
DOI : 10.1007/s00330-011-2319-8

B. Ganeshan, V. Goh, H. C. Mandeville, Q. S. Ng, P. J. Hoskin et al., Non???Small Cell Lung Cancer: Histopathologic Correlates for Texture Parameters at CT, Radiology, vol.266, issue.1, pp.326-336, 2013.
DOI : 10.1148/radiol.12112428

B. France, H. Kras, and . Braf, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts), Biomarkers J. Clin. Oncol

F. Devez, P. Lemaitre, D. Laurent-puig, H. Damotte, and . Blons, Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?, J. Transl. Med, vol.12, pp.131-141, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-00998916

A. F. Gazdar, Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors, Oncogene, vol.19, issue.1, 0198.
DOI : 10.1016/j.cell.2006.05.013